[go: up one dir, main page]

UA113832C2 - Комбінаційна терапія для хозл - Google Patents

Комбінаційна терапія для хозл

Info

Publication number
UA113832C2
UA113832C2 UAA201207626A UAA201207626A UA113832C2 UA 113832 C2 UA113832 C2 UA 113832C2 UA A201207626 A UAA201207626 A UA A201207626A UA A201207626 A UAA201207626 A UA A201207626A UA 113832 C2 UA113832 C2 UA 113832C2
Authority
UA
Ukraine
Prior art keywords
formoterol
range
copd
composition
relates
Prior art date
Application number
UAA201207626A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42107420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA113832(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UA113832C2 publication Critical patent/UA113832C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/003—Adding propellants in fluid form to aerosol containers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B7/00—Closing containers or receptacles after filling
    • B65B7/16—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons
    • B65B7/28—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
    • B65B7/2842—Securing closures on containers
    • B65B7/285—Securing closures on containers by deformation of the closure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)

Abstract

Винахід належить до аерозольної композиції, придатної для введення ХОЗЛ пацієнтам за допомогою інгалятора зі стисненою виміряною дозою (pMDI), що містить глікопіроній бромід в дозі у діапазоні 0,5-100 мкг на одне приведення у дію у комбінації з формотеролом або його сіллю в дозі у діапазоні 1-25 мкг на одне приведення у дію. Композиція додатково містить HFA пропелент, співрозчинник та кількість неорганічної кислоти - 1М НСІ у діапазоні 0,1-0,3 мкг/мкл, достатньої для стабілізації компонентів як глікопіроній броміду, так і формотеролу. Необов’язково композиція додатково містить беклометазон дипропіонат. Винахід також стосується аерозольного контейнера, способу його наповнення та набору із згаданою композицією.
UAA201207626A 2009-12-23 2010-12-22 Комбінаційна терапія для хозл UA113832C2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09180671 2009-12-23
PCT/EP2010/070479 WO2011076843A2 (en) 2009-12-23 2010-12-22 Combination therapy for copd

Publications (1)

Publication Number Publication Date
UA113832C2 true UA113832C2 (xx) 2017-03-27

Family

ID=42107420

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201207626A UA113832C2 (xx) 2009-12-23 2010-12-22 Комбінаційна терапія для хозл

Country Status (40)

Country Link
US (3) US20110150782A1 (uk)
EP (1) EP2515855B3 (uk)
JP (2) JP5914354B2 (uk)
KR (2) KR20170040392A (uk)
CN (2) CN102665679B (uk)
AR (2) AR079726A1 (uk)
AU (2) AU2010334859A1 (uk)
BR (1) BR112012015337B8 (uk)
CA (1) CA2785321C (uk)
CL (1) CL2012001705A1 (uk)
CO (1) CO6541628A2 (uk)
CY (2) CY1115116T1 (uk)
DK (1) DK2515855T6 (uk)
EA (2) EA021917B1 (uk)
ES (1) ES2468840T7 (uk)
FI (2) FI2515855T6 (uk)
GE (1) GEP20156311B (uk)
HR (1) HRP20140582T4 (uk)
HU (1) HUS1800001I1 (uk)
IL (1) IL260932B (uk)
LT (1) LTC2515855I2 (uk)
LU (1) LUC00060I2 (uk)
MA (1) MA33823B1 (uk)
MX (1) MX2012006878A (uk)
MY (1) MY156949A (uk)
NL (1) NL300923I2 (uk)
NO (1) NO2018001I1 (uk)
NZ (1) NZ600790A (uk)
PE (2) PE20160853A1 (uk)
PH (1) PH12012501066A1 (uk)
PL (1) PL2515855T6 (uk)
PT (1) PT2515855E (uk)
RS (1) RS53391B2 (uk)
SG (1) SG181868A1 (uk)
SI (1) SI2515855T1 (uk)
TN (1) TN2012000269A1 (uk)
TW (1) TWI495468B (uk)
UA (1) UA113832C2 (uk)
WO (1) WO2011076843A2 (uk)
ZA (1) ZA201204615B (uk)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2785321C (en) * 2009-12-23 2018-08-21 Chiesi Farmaceutici S.P.A. Combination therapy for copd
WO2011076841A2 (en) * 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
DK2515854T3 (da) 2009-12-23 2014-05-26 Chiesi Farma Spa Aerosolformulering for COPD
EP2749283A3 (en) * 2011-02-17 2014-08-20 Cipla Limited Combination of glycopyrronium and olodaterol
WO2013053696A1 (en) * 2011-10-11 2013-04-18 Chiesi Farmaceutici S.P.A. Crystalline microparticles of a beta-agonist coated with a fatty acid
KR20150096371A (ko) * 2012-10-23 2015-08-24 시플라 리미티드 티오트로피움 및 히드로플루오로알칸을 포함하는 약학적 조성물
RS57799B1 (sr) 2013-07-11 2018-12-31 Chiesi Farm Spa Formulacija suvog praha za administriranje inhalacijom, koja obuhvata atniholinergik, kortikosteroid i beta-adrenergik
PT3096737T (pt) * 2013-12-30 2018-04-27 Chiesi Farm Spa Composição de solução de aerossol pressurizado estável de brometo de glicopirrónio e formoterol
PL3089735T3 (pl) * 2013-12-30 2018-12-31 Chiesi Farmaceutici S.P.A. Trwała ciśnieniowa kompozycja roztworu aerozolowego kombinacji bromku glikopironium i formoterolu
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
GB201416909D0 (en) * 2014-09-25 2014-11-12 Prosonix Ltd Method of forming concentrated solution
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
ES2783855T3 (es) * 2015-11-16 2020-09-18 Chiesi Farm Spa Un proceso para preparar una formulación de polvo seco que comprende un anticolinérgico, un corticoesteroide y un beta-adrenérgico
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
WO2017167737A1 (en) 2016-03-31 2017-10-05 Chiesi Farmaceutici S.P.A. Aerosol inhalation device
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
CN109789131B (zh) * 2016-09-19 2022-08-26 墨西哥氟石股份公司 药物组合物
CN114712338A (zh) 2016-09-19 2022-07-08 墨西哥氟石股份公司 药物组合物
CN109715148A (zh) 2016-09-19 2019-05-03 墨西哥氟石股份公司 药物组合物
MX374484B (es) * 2017-05-11 2025-03-04 Chiesi Farm Spa Proceso para preparacion de una formulacion de polvo seco que incluye un anticolinergico, un corticosteroide y un beta-adrenergico.
CN110582269B (zh) 2017-05-11 2023-02-28 奇斯药制品公司 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
MA52756A (fr) * 2018-06-04 2021-04-14 Lupin Inc Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression
CN114502146A (zh) 2019-12-02 2022-05-13 奇斯药制品公司 用于加压定量吸入器的不锈钢罐
WO2022023515A1 (en) 2020-07-31 2022-02-03 Chemo Research , S.L. Combination therapy for inhalation administration
PE20240629A1 (es) * 2020-10-09 2024-03-26 Chiesi Farm Spa Formulacion farmaceutica para inhalador presurizado de dosis medidas
WO2023227782A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
JP2025521140A (ja) 2022-05-27 2025-07-08 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量噴霧吸入器のための医薬製剤
JP2025517809A (ja) 2022-05-27 2025-06-10 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量噴霧吸入器のための医薬製剤

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
RO117414B1 (ro) 1992-12-09 2002-03-29 Jager Paul D Waterbury Compozitie farmaceutica de aerosol in solutie
US6585958B1 (en) 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
US6475467B1 (en) 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
IT1317720B1 (it) 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
ME00220B (me) * 2000-05-22 2010-10-10 Chiesi Farm Spa Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
EP1372608B1 (de) 2001-03-30 2007-10-10 Jagotec Ag Medizinische aerosolformulierungen
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
ES2779273T3 (es) 2002-03-01 2020-08-14 Chiesi Farm Spa Formulación superfina de formoterol
PL375868A1 (en) 2002-12-16 2005-12-12 Boehringer Ingelheim Pharma Gmbh & Co.Kg Tiotropium containing hfc solution formulations
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
ATE399027T1 (de) * 2004-02-06 2008-07-15 Meda Pharma Gmbh & Co Kg Neue kombination von anticholinergen und beta mimetika zur behanldung von atemwegserkrankungen
ES2413011T3 (es) 2004-02-06 2013-07-15 Meda Pharma Gmbh & Co. Kg Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1616567A1 (en) 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
GB0505545D0 (en) 2005-03-17 2005-04-27 Glaxo Group Ltd Inhalation devices
WO2006105401A2 (en) 2005-03-30 2006-10-05 Schering Corporation Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
BRPI0614436A2 (pt) 2005-08-01 2011-03-29 Astrazeneca Ab válvula inaladora
GB0523654D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
JP5107933B2 (ja) * 2005-12-21 2012-12-26 メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 炎症性疾患の治療に使用する、抗コリン作用薬類、β２−アドレナリン受容体のアゴニスト類、抗ロイコトリエン（ロイコトリエン受容体のアンタゴニスト）類、グルココルチコイド類および／またはＰＤＥ４阻害剤類の新規配合薬
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
MX2010004262A (es) 2007-10-18 2010-05-14 Stiefel Res Australia Pty Ltd Formulaciones topicas de glicopirrolato.
WO2010144628A2 (en) * 2009-06-09 2010-12-16 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
BR112012015335B1 (pt) 2009-12-23 2021-05-18 Chiesi Farmaceutici S.P.A. formulação de aerossol para doença pulmonar obstrutiva crõnica
DK2515854T3 (da) * 2009-12-23 2014-05-26 Chiesi Farma Spa Aerosolformulering for COPD
WO2011076841A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
CA2785321C (en) * 2009-12-23 2018-08-21 Chiesi Farmaceutici S.P.A. Combination therapy for copd
RS57799B1 (sr) * 2013-07-11 2018-12-31 Chiesi Farm Spa Formulacija suvog praha za administriranje inhalacijom, koja obuhvata atniholinergik, kortikosteroid i beta-adrenergik
PT3096737T (pt) 2013-12-30 2018-04-27 Chiesi Farm Spa Composição de solução de aerossol pressurizado estável de brometo de glicopirrónio e formoterol
PL3089735T3 (pl) 2013-12-30 2018-12-31 Chiesi Farmaceutici S.P.A. Trwała ciśnieniowa kompozycja roztworu aerozolowego kombinacji bromku glikopironium i formoterolu
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD

Also Published As

Publication number Publication date
GEP20156311B (en) 2015-07-10
CN102665679B (zh) 2014-11-26
JP2013515696A (ja) 2013-05-09
EA027778B1 (ru) 2017-08-31
PL2515855T6 (pl) 2023-12-18
ZA201204615B (en) 2013-09-25
HUS1800001I1 (hu) 2018-02-28
CY1115116T1 (el) 2016-12-14
CA2785321C (en) 2018-08-21
CY2017047I1 (el) 2018-04-04
TW201129359A (en) 2011-09-01
HK1174566A1 (en) 2013-06-14
WO2011076843A2 (en) 2011-06-30
CY2017047I2 (el) 2018-04-04
FI2515855T6 (fi) 2023-06-02
MA33823B1 (fr) 2012-12-03
WO2011076843A3 (en) 2011-12-01
US20190046433A1 (en) 2019-02-14
NL300923I2 (en) 2019-07-22
KR20170040392A (ko) 2017-04-12
NZ600790A (en) 2014-09-26
US20150328144A1 (en) 2015-11-19
DK2515855T3 (da) 2014-06-30
AR079726A1 (es) 2012-02-15
AU2010334859A1 (en) 2012-07-12
EA201590179A1 (ru) 2015-09-30
BR112012015337B1 (pt) 2021-05-04
US20110150782A1 (en) 2011-06-23
SG181868A1 (en) 2012-07-30
DK2515855T6 (da) 2023-06-06
TN2012000269A1 (en) 2013-12-12
CN102665679A (zh) 2012-09-12
AR115897A2 (es) 2021-03-10
BR112012015337A2 (pt) 2016-03-15
JP6283388B2 (ja) 2018-02-21
BR112012015337B8 (pt) 2021-05-25
EP2515855B1 (en) 2014-04-02
SI2515855T1 (sl) 2014-08-29
LTPA2018001I1 (lt) 2018-02-12
IL260932B (en) 2021-04-29
HRP20140582T1 (hr) 2014-08-01
ES2468840T3 (es) 2014-06-17
CN104055765A (zh) 2014-09-24
PE20121396A1 (es) 2012-10-24
RS53391B2 (sr) 2023-09-29
US11389401B2 (en) 2022-07-19
LUC00060I1 (uk) 2018-01-18
CA2785321A1 (en) 2011-06-30
MX2012006878A (es) 2012-07-04
MY156949A (en) 2016-04-15
CN104055765B (zh) 2016-11-23
CO6541628A2 (es) 2012-10-16
ES2468840T7 (es) 2023-11-29
NO2018001I2 (no) 2018-01-10
US10159645B2 (en) 2018-12-25
KR20120103653A (ko) 2012-09-19
EA021917B1 (ru) 2015-09-30
HRP20140582T4 (hr) 2023-06-09
TWI495468B (zh) 2015-08-11
AU2016234895B2 (en) 2018-02-01
NL300923I1 (en) 2018-01-17
PH12012501066A1 (en) 2016-03-02
CL2012001705A1 (es) 2012-09-28
AU2016234895A1 (en) 2016-10-13
EP2515855B3 (en) 2023-05-03
AU2018202998A1 (en) 2018-05-17
PT2515855E (pt) 2014-06-11
PE20160853A1 (es) 2016-09-14
LTC2515855I2 (lt) 2019-05-10
EP2515855A2 (en) 2012-10-31
KR101757951B1 (ko) 2017-07-13
LUC00060I2 (uk) 2018-03-16
HK1197036A1 (en) 2015-01-02
EA201290375A1 (ru) 2013-01-30
JP5914354B2 (ja) 2016-05-11
FIC20170064I1 (fi) 2017-12-29
RS53391B (sr) 2014-10-31
JP2016145239A (ja) 2016-08-12
NO2018001I1 (no) 2018-01-10
PL2515855T3 (pl) 2014-08-29

Similar Documents

Publication Publication Date Title
UA113832C2 (xx) Комбінаційна терапія для хозл
WO2011076841A3 (en) Combination therapy for copd
MX340924B (es) Composiciones farmaceuticas.
AR038641A1 (es) Formulacion superfina de formoterol
BR112022014228A2 (pt) Inaladores pressurizados de dose calibrada compreendendo uma formulação farmacêutica tamponada
HRP20130835T1 (hr) Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru
UA106098C2 (uk) Аерозольна композиція для хозл
MX336225B (es) Composiciones que comprenden sulfato de salbutamol.
BRPI0515103A (pt) composição farmacêutica, inalador, processos para preparar o mesmo, e uma composição farmacêutica, e, uso de uma composição farmacêutica
GB0323684D0 (en) Improvements in or relating to organic compounds
AR123674A2 (es) Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona
NZ599900A (en) Pharmaceutical suspension aerosol formulations for use in metered dose inhalers
MX2023003754A (es) Formulacion farmaceutica para inhalador presurizado de dosis medidas.
NZ591174A (en) Metered dose inhaler
JP2004529108A5 (uk)
CL2012000947A1 (es) Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis.
WO2004103339A3 (en) Improved metered dose inhaler
TH127043A (th) ผลิตภัณฑ์รวมสำหรับบำบัด copd
BR102012008322B8 (pt) formulações medicinais em aerossol que não debilitam a camada de ozônio e com baixo efeito estufa
CR9941A (es) Formacion farmaceutica de absorcion oral y su metodo de administracion